-
Je něco špatně v tomto záznamu ?
Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity
A. Skalova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
NLK
PubMed Central
od 2007 do Před 1 rokem
Europe PubMed Central
od 2007 do Před 1 rokem
- MeSH
- acinární karcinom diagnóza MeSH
- cystadenokarcinom diagnóza MeSH
- diferenciální diagnóza MeSH
- fúzní onkogenní proteiny genetika MeSH
- imunohistochemie MeSH
- karcinom genetika MeSH
- lidé MeSH
- mukoepidermoidní karcinom diagnóza MeSH
- nádorové biomarkery analýza MeSH
- nádory prsu genetika MeSH
- nádory slinných žláz diagnóza genetika MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Mammary analogue secretory carcinoma of salivary gland origin (MASC) is a recently described tumor with ETV6 translocation. Akin to secretory breast cancer, MASC expresses S-100 protein, mammaglobin, vimentin, and harbors a t(12;15) (p13;q25) translocation which leads to ETV6-NTRK3 fusion product. Histologically, MASC displays a lobulated growth pattern and is often composed of microcystic, tubular, and solid structures with abundant eosinophilic homogeneous or bubbly secretions. Colloid-like secretory material stains positive for periodic acid-Schiff (PAS) with and without diastase and for Alcian blue. The cells of MASC are devoid of PAS-positive secretory zymogen granules. These features help to exclude the most important differential diagnostic considerations, namely acinic cell carcinoma, low-grade cribriform cystadenocarcinoma, cystadenocarcinoma (not otherwise specified), and low-grade mucoepidermoid carcinoma. To date the presence of the ETV6-NTRK3 fusion gene has not been demonstrated in any other salivary gland tumor than MASC. It is likely that MASC is more common than currently recognized and with further studies, the clinical need for molecular studies of the ETV6-NTRK3 fusion may diminish. However, molecular testing is recommended at this time to arrive at the diagnosis of MASC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050944
- 003
- CZ-PrNML
- 005
- 20140410093408.0
- 007
- ta
- 008
- 140401s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12105-013-0455-y $2 doi
- 035 __
- $a (PubMed)23821207
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Skalova, Alena
- 245 10
- $a Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity / $c A. Skalova,
- 520 9_
- $a Mammary analogue secretory carcinoma of salivary gland origin (MASC) is a recently described tumor with ETV6 translocation. Akin to secretory breast cancer, MASC expresses S-100 protein, mammaglobin, vimentin, and harbors a t(12;15) (p13;q25) translocation which leads to ETV6-NTRK3 fusion product. Histologically, MASC displays a lobulated growth pattern and is often composed of microcystic, tubular, and solid structures with abundant eosinophilic homogeneous or bubbly secretions. Colloid-like secretory material stains positive for periodic acid-Schiff (PAS) with and without diastase and for Alcian blue. The cells of MASC are devoid of PAS-positive secretory zymogen granules. These features help to exclude the most important differential diagnostic considerations, namely acinic cell carcinoma, low-grade cribriform cystadenocarcinoma, cystadenocarcinoma (not otherwise specified), and low-grade mucoepidermoid carcinoma. To date the presence of the ETV6-NTRK3 fusion gene has not been demonstrated in any other salivary gland tumor than MASC. It is likely that MASC is more common than currently recognized and with further studies, the clinical need for molecular studies of the ETV6-NTRK3 fusion may diminish. However, molecular testing is recommended at this time to arrive at the diagnosis of MASC.
- 650 _2
- $a nádory prsu $x genetika $7 D001943
- 650 _2
- $a karcinom $x genetika $7 D002277
- 650 _2
- $a acinární karcinom $x diagnóza $7 D018267
- 650 _2
- $a mukoepidermoidní karcinom $x diagnóza $7 D018277
- 650 _2
- $a cystadenokarcinom $x diagnóza $7 D003536
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a fúzní onkogenní proteiny $x genetika $7 D015514
- 650 _2
- $a nádory slinných žláz $x diagnóza $x genetika $7 D012468
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00175647 $t Head and neck pathology $x 1936-0568 $g Roč. 7 Suppl 1, č. - (2013), s. S30-6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23821207 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20140410093457 $b ABA008
- 999 __
- $a ok $b bmc $g 1018080 $s 849524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 7 Suppl 1 $c - $d S30-6 $i 1936-0568 $m Head and neck pathology $n Head Neck Pathol $x MED00175647
- LZP __
- $a Pubmed-20140401